Drugs for pain management, migraines, dry eye disease and Ebola are among those with PDUFA dates – deadlines by which the FDA must review new drug applications – in October. The author of today’s article points out that “PDUFA dates are binary events that invariably serve as make-or-break catalysts for stocks” – and so biotech investors may want to mark these dates on their calendars! For more, CLICK HERE.